Resnick argued Certara’s tools and scientific teams are positioned to benefit from those trends, citing the company’s 430 PhDs and MDs, more than 2,600 customers, and 23 agencies using its technologies. At the same time, he said the company has not converted its credibility into growth commensurate with the opportunity, and he pointed to a mix of factors that could explain the gap, including market acceptance, external headwinds, and internal execution issues.Resnick, who joined the company on Jan. 1, said ...

Core Viewpoint - Certara, Inc. (NASDAQ:CERT) is identified as an oversold value stock with significant upside potential, supported by analyst confidence and recent upgrades despite sector volatility [1][2][3][4]. Group 1: Analyst Sentiment - As of February 5, 2026, 60% of analysts maintain a bullish outlook on Certara, with a consensus price target of $12.00, indicating a 57.70% upside potential [2]. - KeyBanc reduced its price target from $13 to $12 but reiterated an 'Overweight' rating, citing fundamental momentum and a year of inflection for Certara despite industry challenges [3]. - Leerink upgraded Certara from 'Market Perform' to 'Outperform' while keeping the price target at $13, attributing this to the company's leadership in the biosimulation market and viewing the previous selloff as an overreaction [4]. Group 2: Company Overview - Certara focuses on providing software and technology-enabled services for drug developers, including modeling, decision analytics, clinical pharmacology, complex biologics, and regulatory strategy solutions [5].

Core Insights - The health care sector has identified oversold stocks, presenting potential investment opportunities in undervalued companies [1] - The Relative Strength Index (RSI) is a key momentum indicator used to assess stock performance, with an RSI below 30 indicating that a stock is considered oversold [1] Oversold Stocks List - Zai Lab Ltd – ADR (NASDAQ:ZLAB) is among the major oversold players in the health care sector [3] - Vivos Therapeutics Inc (NASDAQ:VVOS) is also listed as an oversold stock [3] - Certara Inc (NASDAQ:CERT) is included in the list of oversold companies [3]

Core Insights - The health care sector has identified oversold stocks, presenting potential investment opportunities in undervalued companies [1] - The Relative Strength Index (RSI) is a key momentum indicator used to assess stock performance, with an RSI below 30 indicating that a stock is considered oversold [1] Oversold Stocks - Zai Lab Ltd – ADR (NASDAQ:ZLAB) is listed as one of the major oversold players in the health care sector [3] - Vivos Therapeutics Inc (NASDAQ:VVOS) is also identified as an oversold stock with an RSI near or below 30 [3] - Certara Inc (NASDAQ:CERT) is included in the list of oversold stocks, indicating potential for recovery [3]

Market Overview - U.S. equity markets in Q4 2025 were influenced by optimism regarding potential monetary easing and caution related to economic growth and valuations [1] - Early gains were driven by strong AI-related earnings and a rate cut by the US Federal Reserve in October, but sentiment cooled later due to mixed signals from the Fed [1] - Large caps rose 17.4% for the year and 2.4% in the quarter, while small caps gained 12.8% for the year and 2.2% in the quarter [1] - Value stocks outperformed growth stocks, returning 3.3% versus 1.2% for the quarter [1] Fund Performance - Meridian Growth Fund delivered a return of -0.39% (net) in the quarter, underperforming the Russell 2500 Growth Index's return of 0.33% [1] - The firm is monitoring factors affecting market returns, including changes in monetary policy and the sustainability of AI investments due to high valuations among hyperscalers [1] - The focus remains on high-quality businesses with strong competitive advantages, solid balance sheets, and clear sustainable earnings growth [1] Company Spotlight: Certara, Inc. - Certara, Inc. (NASDAQ:CERT) was highlighted as a leading relative detractor for the Meridian Growth Fund [2] - Certara offers software products and technology-enabled services for bio-simulation, with shares trading between $8.03 and $15.69 over the past 52 weeks, closing at $10.11 on January 26, 2026 [2] - The company experienced a one-month return of 14.11% but lost 16.65% of its value over the last three months, with a market capitalization of $1.61 billion [2] Certara's Business Dynamics - Certara develops software and services that support drug development through biosimulation, with a majority of recent FDA-approved drugs utilizing its solutions [3] - The company underperformed in the quarter due to weaker-than-expected service bookings, leading to a slight reduction in guidance [3] - With a new CEO adopting a more commercially focused strategy and potential divestiture of a non-core business segment, Certara is positioned to transform into a more focused growth company [3]

Company Overview - Freshworks is a California-based company that develops user-friendly service software aimed at enhancing customer and employee support, utilizing a people-first approach to AI [2] - The company has a strong global presence, serving nearly 75,000 organizations, including notable brands like Bridgestone, Nucor, and S&P Global [1] Financial Performance - Freshworks reported a revenue increase of 15% year-over-year (YOY) to $215.1 million in its fiscal 2025 third-quarter earnings, surpassing analysts' expectations [7] - The company posted a GAAP loss of $0.02 per share, but on an adjusted basis, non-GAAP EPS reached $0.16, reflecting a 45% YOY increase and exceeding Wall Street's estimate by 25.5% [8] - The balance sheet remains robust, with cash, cash equivalents, and marketable securities totaling $813.2 million as of September 30, 2025 [8] Future Outlook - Management anticipates full-year revenue between $833.1 million and $836.1 million, indicating approximately 16% annual growth, with non-GAAP EPS projected between $0.62 and $0.64 [9] - Analysts expect the company's GAAP loss to narrow by nearly 88% in 2025, indicating progress towards sustained profitability [9] Market Sentiment - Freshworks stock currently has a market capitalization of about $3.3 billion and has experienced a 27% decline in 2025, leading to a valuation reset [6] - The stock trades at 16.5 times forward earnings, which is significantly lower than the sector median, placing it in bargain territory [6] - Wall Street maintains a "Moderate Buy" consensus on FRSH, with eight out of 16 analysts recommending a "Strong Buy" [10] Price Targets - The average price target for Freshworks is $18.46, suggesting a potential upside of 57%, while the highest target of $27 indicates a possible increase of 129% [11]

Core Insights - Certara, Inc. operates in the healthcare information services sector, focusing on biosimulation and regulatory expertise to enhance drug development processes [1] - The company's shares are currently priced at $8.74, reflecting an 18% decline over the past year, significantly underperforming the S&P 500 by 34.5 percentage points [2] Company Performance - Certara's stock experienced a sharp decline of approximately 23% following its latest earnings report, which was interpreted as a reset of expectations rather than a fundamental business failure [5] - The company reported a 10% year-over-year revenue growth in the third quarter, with software revenue increasing by 22%, and it returned to positive net income while raising its full-year profitability outlook [5] Investment Activity - Kopion Asset Management acquired an additional 327,064 shares of Certara, valued at approximately $3.37 million, during the quarter ending December 31, indicating confidence in the company's long-term prospects [3][4] - The value of Kopion's position in Certara increased by $645,681 over the quarter, reflecting both new purchases and positive price movement [4] Market Position - Certara's biosimulation software and regulatory services are integral to drug development workflows, characterized by high switching costs and persistent demand, even in tighter budget environments [6] - The company operates in a defensible niche within the pharmaceutical R&D technology market, which may provide resilience against market fluctuations [6]

Core Insights - The healthcare sector's decline presents stock-picking opportunities, but an overall rebound is unlikely [1] - Year-to-date, the healthcare sector (XLV) has underperformed the S&P 500 by 8 percentage points and is on track to underperform for the third consecutive year [1] - Despite low valuations indicating potential upside, robust economic growth, the AI boom, and policy uncertainties may limit overall sector performance [1] - Alpha opportunities are seen as greater than beta returns, with increasing return rate disparities and active M&A activity in the healthcare sector driving stock selection [1] - Goldman Sachs expects M&A activity to continue growing into next year, with nearly half of its M&A concept stock portfolio consisting of healthcare companies [1] Stock Selection - Goldman Sachs has identified specific healthcare stocks from the Russell 1000 index that have recently seen upward revisions in 2026 EPS forecasts and are currently valued below historical levels [2] - Selected stocks include: Jazz Pharmaceuticals (JAZZ.US), Insulet (PODD.US), Sotera Health (SHC.US), Incyte (INCY.US), Regeneron Pharmaceuticals (REGN.US), Biomarin Pharmaceutical (BMRN.US), Universal Health Services (UHS.US), Doximity (DOCS.US), Endocrine Biosciences (NBIX.US), Vertex Pharmaceuticals (VRTX.US), Illumina (ILMN.US), West Pharmaceutical Services (WST.US), DaVita (DVA.US), Edwards Lifesciences (EW.US), Eli Lilly (LLY.US), Zimmer Biomet Holdings (ZBH.US), Penumbra (PEN.US), Nevro (NVST.US), Medtronic (MDT.US), Veeva Systems (VEEV.US), Masimo (MASI.US), Pfizer (PFE.US), Thermo Fisher Scientific (TMO.US), ResMed (RMD.US), Bio-Rad Laboratories (BIO.US), Certara (CERT.US), Align Technology (ALGN.US), Charles River Laboratories International (CRL.US), and Hologic (HOLX.US) [2]

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the impact of AI adoption across various industries, highlighting its transformative effects on how companies operate, invest, and compete since the launch of ChatGPT in late 2022 [3][12][60]. Core Insights - **Increase in AI Adoption Benefits**: - In 3Q25, 24% of companies identified as AI adopters reported measurable impacts from AI, up from 21% in 2Q25 and 15% in 3Q24 [5][20]. - For the broader S&P 500, 15% reported quantifiable benefits, an increase from 11% a year ago [5][20]. - **Sector-Wise Adoption**: - Technology leads with 39% of companies reporting benefits, followed by Communication Services at 26% and Financials at 16% [27][75]. - **Categories of Benefits**: - Companies are seeing quantifiable benefits in six categories: Financial Impact, Productivity Gain, Sales, Marketing & Customer Growth, Product Innovation & Development, Governance, Risk & Security, and Other/Cross-Functional Benefits [15][62]. Financial Metrics and Valuation - **Valuation Comparisons**: - Current free cash flow yield for median large-cap stocks is nearly three times higher than in 2000, and the S&P 500's forward P/E ratio is approximately 35% lower than during the tech bubble [11][35]. - **Market Leadership**: - AI adoption is expected to broaden market leadership over the next 6-12 months, contributing an incremental 30-50 basis points to net margins for the S&P 500 in 2026 and 2027 [9][13]. Macro Environment and Historical Context - **Comparison to 1999-2000**: - Key differences from the late 1990s include stronger balance sheets, higher credit ratings, and deeper liquidity buffers among current companies compared to those during the dot-com era [10][54][55]. - **Economic Cycle**: - The current economic environment is transitioning to an early cycle phase, contrasting with the late cycle of the 1990s, which is expected to support valuations [48][49]. Additional Insights - **AI-Driven Efficiency**: - AI is driving operational efficiencies and is a significant factor in the positive outlook for earnings and market performance [9][13]. - **Investor Sentiment**: - There is ongoing investor interest in understanding the quantifiable benefits of AI adoption, with a systematic analysis of earnings and conference call transcripts revealing increasing mentions of AI benefits [14][60]. Conclusion - The momentum around AI adoption is building, with companies across various sectors reporting tangible benefits. The current macroeconomic environment, characterized by strong financial metrics and a transition to an early cycle, supports a positive outlook for market valuations and earnings growth driven by AI efficiencies.

Core Viewpoint - The market anticipates Opus Genetics, Inc. will report a year-over-year increase in earnings despite lower revenues for the quarter ending September 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus EPS estimate for Opus Genetics is a loss of $0.14 per share, reflecting a year-over-year improvement of +51.7%. Revenues are projected at $2.77 million, down 28.4% from the previous year [3]. - The consensus EPS estimate has been revised down by 4.55% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. - The stock holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [13]. Historical Performance - In the last reported quarter, Opus Genetics was expected to post a loss of $0.25 per share but actually reported a loss of -$0.12, achieving a surprise of +52.00%. Over the last four quarters, the company has beaten consensus EPS estimates three times [14][15]. Industry Context - Certara, Inc., a peer in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings of $0.11 per share for the same quarter, indicating a year-over-year decline of -15.4%. Its revenue is projected to be $105.22 million, up 11% from the previous year [19][20]. The consensus EPS estimate for Certara has been revised up by 77.3% in the last 30 days, but a lower Most Accurate Estimate results in an Earnings ESP of -4.76% [20][21].